H-IVIG Treatment for Severe H1N1 2009

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Treatment with hyperimmune intravenous immunoglobulin (H-IVIG), derived from convalescent plasma from patients recovered from H1N1 2009 influenza A infection, for patients with severe H1N1 2009 infection will decrease mortality, reduce viral load, and shorten the length of stay in ICU and hospital.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intradermal COVID-19 Vaccination in the Immunocompromised

NCT05736913

COVID-19

UNKNOWN PHASE2

Human COVID-19 Immunoglobulin (COVID-HIG) Therapy for COVID-19 Patients

NCT05173441

COVID-19

UNKNOWN PHASE2

SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients

NCT04521309

COVID-19

COMPLETED PHASE1/PHASE2

Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients

NCT04891172

Covid19

UNKNOWN PHASE2/PHASE3

IVIG in Patients With Severe COVID-19 Requiring Mechanical Ventilation

NCT04616001

Covid19 SARS-CoV Infection

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Since the emergence of the novel swine origin influenza A virus (H1N1 2009) in Mexico in March 2009, the virus has led to a pandemic in over 170 countries, resulting in over 180 thousands microbiologically confirmed cases and over 18000 mortality. This strain represents a quadruple re-assortment of two swine strains, one human strain, and one avian strain of influenza. Although the H1N1 2009 is causing a mild disease and has a relatively low mortality rate currently in Hong Kong, severe cases have been reported.

Patients infected with severe H1N1 2009 have overwhelmed the intensive care services in these countries and the mortality has rose up to 6% in Argentina and Brazil, and 0.4% in Australia. This is very much higher than the 0.06% mortality rate of the seasonal flu. Furthermore, there were reports of H1N1 2009 oseltamivir resistance and zanamivir is difficult to be delivered to the consolidated lungs in the severe cases when such drug is most needed. In Hong Kong, vaccination for the H1N1 2009 was prioritised to the older people aged 65 or above with chronic illness, younger people with chronic illness and health care workers. The healthy adults aged 18 to 65, who are most at risk of developing severe H1N1 2009 was not covered by the vaccination program. Experience from 1918 H1N1 pandemic and single case report on the treatment for severe H5N1 infection (Zhou et al. 2007) showed that hyperimmune convalescent plasma is useful (Luke et al. 2006). Mice experiments also showed that antibody therapy is highly effective in the case of H5N1 infection (Heltzer ML et al. 2009, Writing Committee of the Second World Heath Organization, 2008). Therefore, convalescent plasma from patients recovered from H1N1 2009 infection can be harvested to prepare for hyperimmune intravenous immunoglobulin (H-IVIG) and the prepared H-IVIG can be assessed in a randomised controlled trial for treatment of patients with severe H1N1 2009 infection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Novel 2009 Influenza A (H1N1) Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intravenous immunoglobulin

Single intravenous infusion of 0.4g/kg of simple IVIG which contain no H1N1 2009 antibody (manufactured before 2009).

Group Type ACTIVE_COMPARATOR

Intravenous immunoglobulin

Intervention Type DRUG

Single intravenous infusion of 0.4g/kg of simple IVIG

Hyperimmune intravenous immunoglobulin

Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG fractionated from convalescent plasma (H1N1 2009 antibody titer was 1:320 by hemagglutination inhibition and neutralizing antibody assays)

Group Type EXPERIMENTAL

Hyperimmune intravenous immunoglobulin

Intervention Type DRUG

Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyperimmune intravenous immunoglobulin

Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG

Intervention Type DRUG

Intravenous immunoglobulin

Single intravenous infusion of 0.4g/kg of simple IVIG

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

H-IVIG IVIG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (fulfill all criteria): male or female patients 18 years or older
* written informed consent by patient or next of kin (if patients too ill)
* diagnosis of H1N1 2009 infection satisfying both clinical and laboratory criteria:

1. Laboratory criteria: at least one RT-PCR positive for H1N1 2009 from one of the clinical specimens (NPA, ETA, blood, urine or stool).
2. Clinical criteria: patients admitted to ICU with severe community acquired pneumonia as defined by a CURB-65 score of 3 or more
* deterioration during treatment with optimal antiviral (oral or inhaler agents only) and typical and atypical antimicrobial coverage
* required ICU and ventilatory support and within 7 days onset of symptoms.

Exclusion Criteria

* age below 18 years
* known hypersensitivity to immune globulin or any components of the formulation
* known IgA deficiency
* acquire the H1N1 2009 infection from health care facility
* moribund patients or refusal of informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No